AIM: To identify the prevalence of pre-S2 start codon mutations and to assess their association with liver disease progression. METHODS: The mutations were identified by direct sequencing from 73 asymptomatic carriers...AIM: To identify the prevalence of pre-S2 start codon mutations and to assess their association with liver disease progression. METHODS: The mutations were identified by direct sequencing from 73 asymptomatic carriers, 66 chronic hepatitis (CH), 66 liver cirrhosis (LC) and 63 hepatocellular carcinoma (HCC) patients. Statistical significances were determined using Fisher's exact test, χ 2 test, and t -test analyses whenever appropriate. Pre-S mutation as a risk factor for advanced liver disease was estimated by unconditional logistic regression model adjusted with age, sex, and hepatitis B e antigen (HBeAg). P < 0.05 was considered significant. RESULTS: Mutation of the hepatitis B virus (HBV) pre-S2 start codon was found in 59 samples from 268 subjects (22.0%), with higher prevalence in patients with cirrhosis 27/66 (40.9%) followed by HCC 18/63 (28.6%), chronic hepatitis 12/66 (18.2%) and asymptomatic carriers 2/73 (2.7%) (P < 0.001). Logistic regression analysis showed that pre-S2 start codon mutation was an independent factor for progressive liver disease. Other mutations, at T130, Q132, and A138, were also associated with LC and HCC, although this was not statistically significant when adjusted for age, sex, and HBeAg. The prevalence of pre-S2 start codon mutation was higher in HBV/B than in HBV/C (23.0% vs 19.1%), whilst the prevalence of T130, Q132, and A138 mutation was higher in HBV/C than in HBV/B. The prevalence of pre-S2 start codon mutation was higher in LC (38.9%) and HCC (40.0%) than CH (5.6%) in HBeAg(+) group, but it was similar between CH, LC and HCC in HBeAg(-) group. CONCLUSION: Pre-S2 start codon mutation was higher in Indonesian patients compared to other Asian countries, and its prevalence was associated with advanced liver disease, particularly in HBeAg(+) patients.展开更多
目的本研究旨在探讨老年T2DM病人血清糖类抗原19-9(CA19-9)的水平及其影响因素。方法选择2019年3~10月在我院内分泌科住院的536例老年T2DM病人,检测其CA19-9及糖脂代谢相关指标水平,并记录病人使用的降糖药物和微血管并发症发生情况。...目的本研究旨在探讨老年T2DM病人血清糖类抗原19-9(CA19-9)的水平及其影响因素。方法选择2019年3~10月在我院内分泌科住院的536例老年T2DM病人,检测其CA19-9及糖脂代谢相关指标水平,并记录病人使用的降糖药物和微血管并发症发生情况。比较不同CA19-9水平病人的临床特征。采用Spearman相关分析和多元逐步回归分析评价CA19-9水平的影响因素。结果老年T2DM病人CA19-9水平升高的发生率为7.5%。CA19-9<37 U/mL组和CA19-9≥37 U/mL组间LDL-C、HbA1c、血钙、餐后2 h C肽水平差异有统计学意义(P<0.05或0.01)。使用双胍类药物的病人的CA19-9水平低于使用非双胍类药物的病人(P<0.01)。Spearman相关分析结果显示,CA19-9与年龄、TC、TG、CRP、HbA1c呈正相关(P<0.05),与血清白蛋白及餐后2 h C肽呈负相关(P<0.05)。多元逐步回归分析结果显示,HbA1c是CA19-9的独立影响因素。结论使用二甲双胍的老年T2DM病人可能具有较低水平的CA19-9。老年T2DM病人的CA19-9水平与血糖控制效果密切相关。展开更多
The DNA fragments coding for preS2(120 146) and preS1(21 47) amplified by PCR were fused to both 5′ and 3′ ends of S gene at the position of amino acid 223. The fusion gene was placed downstream of the promoter P7.5...The DNA fragments coding for preS2(120 146) and preS1(21 47) amplified by PCR were fused to both 5′ and 3′ ends of S gene at the position of amino acid 223. The fusion gene was placed downstream of the promoter P7.5 of the universal vaccinia viral vector pGJP 5 and the recombinant vaccinia virus vS2SS1 was then selected by \%in vivo\% homogeneous recombination. Fusion protein S2SS1 could be expressed in the mammalian cells infected with vS2SS1. The investigation of expression, secretion, antigenicity and particle assembly of the S2SS1 protein demonstrated that S2SS1 protein could be assembled into particles which presented preS1, preS2 and S antigenicity and be efficiently secreted from the cells. It also showed that the level of its expression and secretion approached to that of the S protein expressed by the recombinant vaccinia virus.展开更多
目的探讨前列腺健康指数(prostate health index,PHI)及其衍生指标在前列腺多参数核磁中PI-RADS-3病变的前列腺癌中的诊断价值。方法回顾性分析石家庄市人民医院2019至2022年204例前列腺特异性抗原(PSA)检测值异常病并行超声引导下前列...目的探讨前列腺健康指数(prostate health index,PHI)及其衍生指标在前列腺多参数核磁中PI-RADS-3病变的前列腺癌中的诊断价值。方法回顾性分析石家庄市人民医院2019至2022年204例前列腺特异性抗原(PSA)检测值异常病并行超声引导下前列腺活检的患者数据,将155例良性前列腺增生的患者作为良性前列腺增生组,49例前列腺癌患者作为前列腺癌组。收集2组患者临床数据,利用受试者工作特征(ROC)曲线评价不同亚组中总前列腺特异性抗原(TPSA)、游离/总前列腺特异性抗原(%fPSA)、PHI、前列腺健康指数密度(PHID)和总前列腺特异性抗原密度(PSAD)对于前列腺癌的诊断价值。结果49例患有前列腺癌中81.63%的病例诊断为临床显著性前列腺癌(csPCa)。2组年龄、前列腺体积(PV)、TPSA和PSAD差异无统计学意义(P>0.05)。前2肽前列腺特异性抗原(p2PSA)、PHI和PHID比较,差异均有统计学意义(P<0.05)。与TPSA相比,PHI(AUC=0.786,95%CI:0.705~0.867)和PHID(AUC=0.763,95%CI:0.684~0.843)是前列腺癌更好的预测指标。TPSA、%fPSA、p2PSA、PHI、PHID和PSAD区域在csPCa组的ROC曲线面积分别为0.587、0.650、0.696、0.823、0.796和0.614。所有参数中PHI和PHID对于前列腺癌的预测结果最准确。结论在PI-RADS-3病变的情况下,相较于传统指标,前列腺健康指数及其衍生指标为前列腺癌的检出提供了最佳的诊断价值。展开更多
基金Supported by MRIN Funding, Budget, No. cc041/2010
文摘AIM: To identify the prevalence of pre-S2 start codon mutations and to assess their association with liver disease progression. METHODS: The mutations were identified by direct sequencing from 73 asymptomatic carriers, 66 chronic hepatitis (CH), 66 liver cirrhosis (LC) and 63 hepatocellular carcinoma (HCC) patients. Statistical significances were determined using Fisher's exact test, χ 2 test, and t -test analyses whenever appropriate. Pre-S mutation as a risk factor for advanced liver disease was estimated by unconditional logistic regression model adjusted with age, sex, and hepatitis B e antigen (HBeAg). P < 0.05 was considered significant. RESULTS: Mutation of the hepatitis B virus (HBV) pre-S2 start codon was found in 59 samples from 268 subjects (22.0%), with higher prevalence in patients with cirrhosis 27/66 (40.9%) followed by HCC 18/63 (28.6%), chronic hepatitis 12/66 (18.2%) and asymptomatic carriers 2/73 (2.7%) (P < 0.001). Logistic regression analysis showed that pre-S2 start codon mutation was an independent factor for progressive liver disease. Other mutations, at T130, Q132, and A138, were also associated with LC and HCC, although this was not statistically significant when adjusted for age, sex, and HBeAg. The prevalence of pre-S2 start codon mutation was higher in HBV/B than in HBV/C (23.0% vs 19.1%), whilst the prevalence of T130, Q132, and A138 mutation was higher in HBV/C than in HBV/B. The prevalence of pre-S2 start codon mutation was higher in LC (38.9%) and HCC (40.0%) than CH (5.6%) in HBeAg(+) group, but it was similar between CH, LC and HCC in HBeAg(-) group. CONCLUSION: Pre-S2 start codon mutation was higher in Indonesian patients compared to other Asian countries, and its prevalence was associated with advanced liver disease, particularly in HBeAg(+) patients.
文摘目的本研究旨在探讨老年T2DM病人血清糖类抗原19-9(CA19-9)的水平及其影响因素。方法选择2019年3~10月在我院内分泌科住院的536例老年T2DM病人,检测其CA19-9及糖脂代谢相关指标水平,并记录病人使用的降糖药物和微血管并发症发生情况。比较不同CA19-9水平病人的临床特征。采用Spearman相关分析和多元逐步回归分析评价CA19-9水平的影响因素。结果老年T2DM病人CA19-9水平升高的发生率为7.5%。CA19-9<37 U/mL组和CA19-9≥37 U/mL组间LDL-C、HbA1c、血钙、餐后2 h C肽水平差异有统计学意义(P<0.05或0.01)。使用双胍类药物的病人的CA19-9水平低于使用非双胍类药物的病人(P<0.01)。Spearman相关分析结果显示,CA19-9与年龄、TC、TG、CRP、HbA1c呈正相关(P<0.05),与血清白蛋白及餐后2 h C肽呈负相关(P<0.05)。多元逐步回归分析结果显示,HbA1c是CA19-9的独立影响因素。结论使用二甲双胍的老年T2DM病人可能具有较低水平的CA19-9。老年T2DM病人的CA19-9水平与血糖控制效果密切相关。
文摘The DNA fragments coding for preS2(120 146) and preS1(21 47) amplified by PCR were fused to both 5′ and 3′ ends of S gene at the position of amino acid 223. The fusion gene was placed downstream of the promoter P7.5 of the universal vaccinia viral vector pGJP 5 and the recombinant vaccinia virus vS2SS1 was then selected by \%in vivo\% homogeneous recombination. Fusion protein S2SS1 could be expressed in the mammalian cells infected with vS2SS1. The investigation of expression, secretion, antigenicity and particle assembly of the S2SS1 protein demonstrated that S2SS1 protein could be assembled into particles which presented preS1, preS2 and S antigenicity and be efficiently secreted from the cells. It also showed that the level of its expression and secretion approached to that of the S protein expressed by the recombinant vaccinia virus.
文摘目的探讨前列腺健康指数(prostate health index,PHI)及其衍生指标在前列腺多参数核磁中PI-RADS-3病变的前列腺癌中的诊断价值。方法回顾性分析石家庄市人民医院2019至2022年204例前列腺特异性抗原(PSA)检测值异常病并行超声引导下前列腺活检的患者数据,将155例良性前列腺增生的患者作为良性前列腺增生组,49例前列腺癌患者作为前列腺癌组。收集2组患者临床数据,利用受试者工作特征(ROC)曲线评价不同亚组中总前列腺特异性抗原(TPSA)、游离/总前列腺特异性抗原(%fPSA)、PHI、前列腺健康指数密度(PHID)和总前列腺特异性抗原密度(PSAD)对于前列腺癌的诊断价值。结果49例患有前列腺癌中81.63%的病例诊断为临床显著性前列腺癌(csPCa)。2组年龄、前列腺体积(PV)、TPSA和PSAD差异无统计学意义(P>0.05)。前2肽前列腺特异性抗原(p2PSA)、PHI和PHID比较,差异均有统计学意义(P<0.05)。与TPSA相比,PHI(AUC=0.786,95%CI:0.705~0.867)和PHID(AUC=0.763,95%CI:0.684~0.843)是前列腺癌更好的预测指标。TPSA、%fPSA、p2PSA、PHI、PHID和PSAD区域在csPCa组的ROC曲线面积分别为0.587、0.650、0.696、0.823、0.796和0.614。所有参数中PHI和PHID对于前列腺癌的预测结果最准确。结论在PI-RADS-3病变的情况下,相较于传统指标,前列腺健康指数及其衍生指标为前列腺癌的检出提供了最佳的诊断价值。
